Other
Liver Resection
0
Pipeline Programs↗
4
Active Trials↗
0
Companies Involved↗
Liver Resection is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
27
clinical trials
Completed12 · 44%
Terminated7 · 26%
Unknown status4 · 15%
Recruiting3 · 11%
Not yet recruiting1 · 4%
Clinical Trials
Trial Activity
27 trials
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection
Not yet recruiting·—·N/A·NCT07077798·234 enrolled
A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection
Completed·—·Phase 2·NCT00819650·200 enrolled
A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
Completed·—·Phase 2·NCT00820053·450 enrolled
Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.
Completed·—·Phase 2·NCT02588716·84 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)